Evidence map›Paper›PMID 28664316›Full record

ArticlePharmaceutical research2017

Galactosyl Pentadecene Reversibly Enhances Transdermal and Topical Drug Delivery.

Monika Kopečná, Miloslav Macháček, Eva Prchalová, Petr Štěpánek, Pavel Drašar, Martin Kotora, Kateřina Vávrová

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  3. Article
  4. Antiaging Properties ofMolecules (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Frontiers in pharmacology · 2024
    Article
  7. Article
  8. Article
  9. Pharmaceutics · 2021
    Article
  10. Article
  11. Bacterial Cellulose Membrane ContainingInternational journal of molecular sciences · 2021
    Article
  12. Article
  13. Molecules (Basel, Switzerland) · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Transepidermal water loss and skin conductance as barrier integrity tests.Toxicology in vitro : an international journal published in association with BIBRA · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Monika KopečnáSkin Barrier Research Group,, Charles University, Faculty of Pharmacy in Hradec Králové,, Akademika Heyrovského 1203,, 50005, Hradec Králové, Czech Republic.
Miloslav MacháčekDepartment of Biochemical Sciences,, Charles University Faculty of Pharmacy in Hradec Králové,, Akademika Heyrovského 1203,, 50005, Hradec Králové, Czech Republic.
Eva PrchalováInstitute of Organic Chemistry and Biochemistry AS CR, Flemingovo náměstí 2,, 166 10, Praha 6, Czech Republic.
Petr ŠtěpánekDepartment of Chemistry of Natural Compounds,, University of Chemical Technology, Technická 5, 166 28, 6 - Dejvice, Praha, Czech Republic.
Pavel DrašarDepartment of Chemistry of Natural Compounds,, University of Chemical Technology, Technická 5, 166 28, 6 - Dejvice, Praha, Czech Republic.
Martin KotoraInstitute of Organic Chemistry and Biochemistry AS CR, Flemingovo náměstí 2,, 166 10, Praha 6, Czech Republic.
Kateřina VávrováSkin Barrier Research Group,, Charles University, Faculty of Pharmacy in Hradec Králové,, Akademika Heyrovského 1203,, 50005, Hradec Králové, Czech Republic. katerina.vavrova@faf.cuni.cz.ORCID http://orcid.org/0000-0002-8502-4372
Charles University · CZUniversity of Chemistry and Technology, Prague · CZCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZ

Funding

Grantová Agentura České Republiky 13-23891SGrantová Agentura, Univerzita Karlova 88615Univerzita Karlova v Praze SVV260401
6 · The paper itself

Abstract

purposeTo study new skin penetration/permeation enhancers based on amphiphilic galactose derivatives.

methodsTwo series of alkyl and alkenyl galactosides were synthesized and evaluated for their enhancing effect on transdermal/topical delivery of theophylline (TH), hydrocortisone (HC) and cidofovir (CDV), reversibility of their effects on transepidermal water loss (TEWL) and skin impedance, interaction with the stratum corneum using infrared spectroscopy, and cytotoxicity on keratinocytes and fibroblasts.

resultsInitial evaluation identified 1-(α-D-galactopyranosyl)-(2E)-pentadec-2-ene A15 as a highly potent enhancer - it increased TH and HC flux through human skin 8.5 and 5 times, respectively. Compound A15 increased the epidermal concentration of a potent antiviral CDV 7 times over that reached by control and Span 20 (an established sugar-based enhancer). Infrared spectroscopy of human stratum corneum indicated interaction of A15 with skin barrier lipids but not proteins. These effects of A15 on the skin barrier were reversible (both TEWL and skin impedance returned to baseline values within 24 h after A15 had been removed from skin). In vitro toxicity of A15 on HaCaT keratinocytes and 3T3 fibroblasts was acceptable, with IC

conclusionsGalactosyl pentadecene A15 is a potent enhancer with low toxicity and reversible action.

Indexed as

Administration, CutaneousAlkenesCidofovirCytosineDrug LiberationEpidermisFibroblastsGalactoseGalactosidesHumansHydrocortisoneKeratinocytesLipidsOrganophosphonatesPermeabilitySkinAlkenesCidofovirCytosineGalactoseGalactosidesHydrocortisoneLipidsOrganophosphonatesTheophyllineWatergalactosidepenetration enhancerssugartopical drug deliverytransdermal drug delivery

Identifiers

PMID28664316
OpenAlexW2729653385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.